15 September 2020 in Gut and Liver
Yasunobu Yamashita, Kensuke Tanioka, Yuki Kawaji, Takashi Tamura, Junya Nuta, Keiichi Hatamaru, Masahiro Itonaga, Takeichi Yoshida, Yoshiyuki Ida, Takao Maekita, Mikitaka Iguchi, and Masayuki Kitano. Gut and Liver 1999;0:. https://doi.org/10.5009/gnl19170
26 August 2026 in Cancer Discovery
Pancreatic ductal adenocarcinoma (PDAC) arises from precursor lesions over a decade-plus, offering a window for interception in high-risk individuals, but current surveillance detects a minority of precursors. Mutant KRAS (mKRAS) is present in most PDACs and their precursors, making it an appealing target for immune-based interception. We conducted a phase I, first-in-human study of a peptide vaccine targeting 6 common KRAS mutations (mKRAS-VAX) in 20 individuals with hereditary PDAC predisposition and a radiographic pancreatic abnormality (NCT05013216) to assess safety, immunogenicity, and T-cell persistence. Adverse events were grade 1 to 2. Vaccination elicited a significant mKRAS-specific T-cell response in 18 of 20 (90%) participants. Longitudinal T-cell receptor sequencing demonstrated persistence of vaccine-induced mKRAS-specific clonotypes for up to 2 years. Over a median follow-up of 16.5 months, no participants developed PDAC. These findings demonstrate that mKRAS-VAX is safe and generates durable T-cell responses, which support the advancement of mKRAS-targeted vaccination for PDAC interception. Significance: In high-risk individuals with hereditary predisposition to PDAC, a first-in-human peptide vaccine targeting mKRAS (mKRAS-VAX) was safe and elicited durable T-cell responses, supporting further development of mKRAS-targeted vaccination for immune interception for pancreatic precancers.
30 September 2025 in Cancer Epidemiology, Biomarkers & Prevention
Background: Cancer antigen 125 (CA125) is widely recognized as a useful biomarker for the surveillance of patients with ovarian and other cancers. Prior genome-wide association studies have identified variants that influence CA125 levels. We evaluated the utility of stratifying CA125 levels by such variants and evaluated diagnostic performance in control subjects and patients with pancreatic ductal adenocarcinoma (PDAC). Methods: We measured CA125 levels in 807 control subjects and 450 patients with PDAC and genotyped 10 variants involving four genes (GAL3ST2, MSLN, D2HGDH, and MUC16). We compared CA125 levels in controls by variant and generated variant-defined CA125 cutoffs and then classified cases and controls into functional groups based on their variant profile. We used this variant classification to evaluate the diagnostic performance of CA125 in patients with PDAC. Results: Six variants associated with CA125 levels were used to group controls into one of four groups. Mean CA125 levels in the highest variant group were approximately fourfold higher than in the lowest group. African Americans were more likely to have a variant group associated with low CA125 levels. After setting diagnostic cutoffs by variant group, the diagnostic sensitivity of CA125 for PDAC was 20.2% at 98% specificity (areas under the ROC curve, 0.702), not significantly different from a uniform CA125 diagnostic cutoff (areas under the ROC curve, 0.700). Conclusions: Gene variants can be used to generate personalized CA125 reference ranges. This approach did not significantly improve CA125’s diagnostic performance for pancreatic cancer, but it merits evaluation in other diagnostic settings, such as detecting ovarian cancer. Impact: Gene variants can be used to personalize CA125 levels.